ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Consumer Health Apps and Digital Health Tools Proliferate, Improving Quality and Health Outcomes for Patients, Says New Report from IQVIA Institute

July 22, 2021 GMT

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul 22, 2021--

Digital health tools are increasingly having a positive impact on health outcomes. Some are becoming integral parts of mainstream medicine, according to findings released today by the IQVIA Institute for Human Data Science in a new report, Digital Health Trends 2021: Innovation, Evidence, Regulation, and Adoption.

The number of consumer health apps continues to grow with more than 90,000 news apps released in 2020. According to the report, that makes more than 350,000 apps currently available for consumers. Furthermore, apps are increasingly focused on helping consumers manage their health conditions rather than on wellness management. Consumer disease management apps now account for 47 percent of the most widely used digital health apps in 2020, up from 28 percent in 2015. Apps for mental health, diabetes, and cardiovascular care account for almost half of the disease-specific apps. Simultaneously, digital therapeutics and digital care products are growing in volume and gaining reimbursements.

ADVERTISEMENT

Evidence of the positive impact on health outcomes from the use of digital tools is also increasing and becoming more robust. This evidence supports inclusion of these tools in treatment guidelines for an expanded set of health conditions. At the same time, validated wearables and digital biomarkers are more numerous. These devices are gaining adoption in clinical trials and are enabling remote monitoring of patients.

“We are finding evidence of a growing maturity of digital health tools in mainstream medicine,” said Murray Aitken, IQVIA senior vice president and executive director of the IQVIA Institute for Human Data Science. “While there has been a significant growth in apps and digital health tools since 2013, we are beginning to detect improved quality of the digital health tools in the management of health conditions. These quality improvements result in robust evidence of their impact on patient outcomes and subsequent inclusion in clinical practice. The growing success of digital health is a testament to the value and sustained impact of its innovation that bodes well for further advances in medicine and healthcare moving forward.”

A few key highlights of the report include:

  • Growing maturity of digital health tools: Multiple types of digital health tools contributed to reducing the impact of the COVID-19 pandemic. These tools are now established parts of the digital health landscape. Consumer apps are the most widely used digital health tools, shifting rapidly toward disease-specific needs. But quality is inconsistent, and consumers need to be selective.

ADVERTISEMENT

  • Digital Therapeutics and Digital Care products: Incorporating software as a means to treat, prevent or manage specific diseases or conditions has increased. More than 250 such products are now identified, including about 150 products commercially available and the rest in development.

  • Wearables and digital biomarkers: The use of wearables, connected sensors and digital biomarkers is expanding. They are gaining adoption in clinical trials and enabling remote monitoring of patients that can influence care delivery. Activity monitoring devices that measure heart rate, steps taken, distance traveled, and calories burned account for about 55 percent of the 384 wearable devices currently marketed to consumers. Sensors and digital biomarkers are being incorporated into the design of clinical trials for pharmaceuticals and medical devices and are enabling decentralized and hybrid trials with home visits that reduce patient and investigator burden and accelerate clinical trial timelines.

  • Evidence: The body of evidence around the effectiveness of digital health apps is now substantial and supports the inclusion of digital health tools in treatment guidelines for an expanded set of health indications. These include cardiovascular applications and the management of some chronic conditions (e.g., pain). More than 2,000 efficacy studies have been published since 2007, including almost 1,500 published in the past five years.

  • Commercialization: Multiple commercialization pathways now exist for digital health tools. This expanded access offers opportunities for developers to attain an economic return on investment for those tools supported by robust evidence and user demand. Four broad commercial models are now in place and being used to pay or reimburse digital tool developers. Those models are direct-to-consumer, value-based contracting, “device-like” reimbursement and “drug-like” reimbursement models.

The full version of the report, including a detailed description of the methodology, is available at www.IQVIAInstitute.org. The study was produced independently as a public service, without industry or government funding.

About the IQVIA Institute for Human Data Science

The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.

Fulfilling an essential need within healthcare, the Institute delivers objective, relevant insights and research that accelerate understanding and innovation critical to sound decision making and improved human outcomes. With access to IQVIA’s institutional knowledge, advanced analytics, technology and unparalleled data, the Institute works in tandem with a broad set of healthcare stakeholders to drive a research agenda focused on Human Data Science, including government agencies, academic institutions, the life sciences industry, and payers. More information about the IQVIA Institute can be found at www.IQVIAInstitute.org.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 72,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210722005256/en/

CONTACT: Nick Childs, IQVIA Investor Relations (Nchilds@us.imshealth.com)

+1.973.316.3828

Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)

+1.484.567.6732

KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA

INDUSTRY KEYWORD: HARDWARE DATA MANAGEMENT CONSUMER ELECTRONICS OTHER HEALTH TECHNOLOGY GENERAL HEALTH FITNESS & NUTRITION OTHER TECHNOLOGY SCIENCE BIOTECHNOLOGY SOFTWARE OTHER SCIENCE HEALTH MOBILE/WIRELESS RESEARCH

SOURCE: IQVIA

Copyright Business Wire 2021.

PUB: 07/22/2021 08:00 AM/DISC: 07/22/2021 08:02 AM

http://www.businesswire.com/news/home/20210722005256/en